Skip to content

Treatment of Incomplete Abortion With 600 Mcg Oral Misoprostol Compared to Standard Surgical Treatment

Misoprostol for Treatment of Incomplete Abortion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00674232
Enrollment
311
Registered
2008-05-07
Start date
2006-05-31
Completion date
2007-10-31
Last updated
2008-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incomplete Abortion

Keywords

incomplete abortion, spontaneous miscarriage

Brief summary

This study aims to compare the efficacy, side effects profile and acceptability of a single dose of 600mcg misoprostol taken orally compared to standard surgical treatment as per local protocols for the treatment of incomplete abortion.

Interventions

DRUG600 mcg misoprostol

single dose of misoprostol taken orally

PROCEDURESurgical treatment

Either dilation and curettage or manual vacuum aspiration, as per local protocol

Sponsors

Gynuity Health Projects
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
14 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* past or present history of vaginal bleeding during pregnancy * open cervical os * evidence of incomplete abortion with substantial debris in the uterus (if using ultrasound) * surgical evacuation of the uterus would be advised as course of action if misoprostol was not available * generally in good health * woman lives or works within one hour of study site * woman willing to provide contact information for follow up purposes * informed consent given

Exclusion criteria

* contraindications to study drug * uterine size larger than 12 weeks LMP * signs of severe infection

Design outcomes

Primary

MeasureTime frame
complete resolution of signs/symptoms of incomplete abortion without recourse to surgery at any point for any reasonone week after initial treatment

Secondary

MeasureTime frame
side effectsmeasured at follow up visit one week after initial treatment
acceptabilitymeasured at follow up visit one week after initial treatment

Countries

Ecuador, Venezuela

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026